Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces “At-The-Market” Equity Program

CAMBRIDGE, Mass., May 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
April 08, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

First patients in the 1.4 mg/kg cohort of TTI-621 and the 8.0 mg/kg cohort of TTI-622 clinical studies have been dosed. Going forward, expect a slow-down or potentially a pause in enrollment of new...
March 10, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Reports Annual Financial and Operating Results

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
February 28, 2020 12:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Responds to Market Activity

CAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL)...
February 07, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Announces Changes to Its Board of Directors

Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”)...
January 29, 2020 07:00 ET | Source: Trillium Therapeutics Inc.

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
January 23, 2020 08:15 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
January 22, 2020 16:01 ET | Source: Trillium Therapeutics Inc.

Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

CAMBRIDGE, Mass., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
January 16, 2020 08:00 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
January 07, 2020 08:30 ET | Source: Trillium Therapeutics Inc.

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

Intravenous TTI-621 dose escalation under initial dose limiting toxicity (DLT) criteria now completed – confirms TTI-621 monotherapy activity (including complete responses) in hematologic malignancies...